Anomalous origin of the right coronary artery from the pulmonary artery is rare (only 200 cases have been reported in total), potentially life-threatening and with an uncertain prognosis. Patient characteristics are only available in half the reported cases. Easy to miss, anomalous origin of the right coronary artery from the pulmonary artery (ARCAPA) is usually diagnosed in association with concomitant cardiac anomalies. Techniques for its correction are rarely discussed, but the restoration of a two-coronary system is optimal. We report details of the surgical repair of ARCAPA in a 17-year-old man to highlight important anatomical features.
ФГБУ "Федеральный центр сердечно-сосудистой хирургии" Минздрава России. Пенза, Россия Цель. Определить частоту развития острого почечного повреждения (ОПП), в т. ч. потребность в заместительной почечной терапии (ЗПТ), выявить факторы риска, оценить исходы ОПП. Материал и методы. В исследование включены 2958 пациентов после различных видов кардиохирургических операций. Стадия ОПП и показания к ЗПТ выставлялись на основании критериев Kidney Disease: Improving Global Outcomes. Результаты. Частота развития ОПП в общей группе составила 14%. ОПП 1 стадии диагностирована у 10,2% (n=303) пациентов, ОПП 2 стадии у 3% (n=88), ОПП 3 стадии 0,8% (n=23) пациентов. ЗПТ проводилась у 1,3% (n=38) пациентов. Частота развития ОПП после изолированного коронарного шунтирования (КШ) составила 9,5% (n=35), изолированного протезирования клапанов (ПрК) и/или пластики клапанов (ПлК) 19,8% (n=35), КШ+ПрК/ ПлК 33% (n=84), комбинированные операции 19,5% (n=107). Потребность в ЗПТ после КШ -0,3% (n=6), после ПрК/ПлК -0,56% (n=1), после КШ+ПрК/ПлК -5,5% (n=14), после комбинированных операций -3% (n=17). Заключение. Факторы риска ОПП: возраст, индекс массы тела, индекс объема левого предсердия, тип операции, синдром малого сердечного выброса, фибрилляция предсердий в раннем послеоперационном периоде, инотропная и вазопрессорная терапия, лактат-ацидоз. Развитие ОПП увеличивает сроки госпитализации и летальность. Ключевые слова: острое почечное повреждение, факторы риска, заместительная почечная терапия.
<p><strong>Aim.</strong> The purpose of this study was to assess the effectiveness of two types of cardioplegia solutions, namely, blood and crystalloid cardioplegia in terms of clinical outcomes in patients undergoing coronary artery bypass grafting.</p><p><strong>Methods.</strong> The retrospective study recruited 2,539 coronary artery bypass grafting patients, with 1,070 (45%) of them receiving crystalloid and 1,289 (55%) blood cardioplegia as a primary cardioplegic agent. Propensity score matching was performed to create comparable patient groups. The primary endpoint of the study was hospital mortality and different postoperative outcomes.</p><p><strong>Results.</strong> Patients receiving blood cardioplegia versus those with crystalloid cardioplegia were found out to have higher rate of acute kidney injury (15.7% vs 11.8%; OR=0.72; p=0.01) and postoperative ventilatory support (Ме=5:35 vs Me=5; p<0.05). During ventilatory support, the crystalloid cardioplegia patients demonstrated lower hemoglobin (Me=65 g/l vs Me=74 g/l; p<0.01) and hematocrit (Me=21% vs Mе=24%; p<0.01). Intraoperatively, packed red blood cells were administered in blood cardioplegia patients by 30% more often than in crystalloid cardioplegia ones (24% vs 19.6%; OR=0.77; p=0.02). Patients receiving crystalloid cardioplegia had a greater postoperative fluid balance (Me=1,700 ml vs Mе=1,350 ml; p<0.01) more frequent use of inotrope and vasopressor therapy (4.5% vs 2.8%; OR=1.64; p=0.04) and a longer stay in intensive care unit (p<0.01).<br />No statistically significant differences were observed concerning perioperative and postoperative myocardial infarction, low cardiac output syndrome or intra-aortic balloon pumping, allogeneic blood transfusions in the postoperative period, episodes of atrial fibrillation, gastrointestinal complications, reoperation due to any cause, length of stay in hospital, hospital mortality.</p><p><strong>Conclusion.</strong> Blood cardioplegia might decrease the need in inotrope and vasopressor therapy, length of stay in intensive care unit, but it increases the rate of acute kidney injury, risk of allogeneic blood transfusions and durability of postoperative ventilatory support. </p><p>Received 1 August 2018. Revised 18 October 2018. Accepted 22 October 2018.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions</strong><br />Conception and study design: M.E. Evdokimov, A.A. Gornostaev, V.V. Bazylev<br />Data collection and analysis: M.E. Evdokimov, A.A. Gornostaev, A.A. Schegolkov, A.V. Bulygin<br />Statistical analysis: A.A. Schegolkov, A.V. Bulygin<br />Drafting the article: A.A. Schegolkov, A.V. Bulygin<br />Critical revision of the article: M.E. Evdokimov, A.A. Gornostaev, V.V. Bazylev<br />Final approval of the version to be published: V.V. Bazylev, M.E. Evdokimov, A.A. Gornostaev, A.A. Schegolkov, A.V. Bulygin</p>
<p><strong>Aim.</strong> Among cardiac patients, active smokers are not a rarity. Smoking causes a strong addiction and smoking cessation leads to the development of a withdrawal syndrome. Due to forced smoking cessation before surgery, nicotine abstinence may become one of the reasons for the development of delirium in the immediate postoperative period. The study was designed to assess the efficacy of nicotine replacement therapy in the prevention of delirium in smoking patients after isolated myocardial revascularization surgery. <br /><strong>Methods.</strong> From January 2014 to December 2014, 968 patients underwent isolated myocardial revascularization. Four hundred and twenty-eight of the above patients with the length of smoking of more than 10 years were included in the study. Nicotine replacement therapy in the smoking patients consisted of two sequential applications of nicotine patches. The first application was put in the operating room before induction into anesthesia, the second one—after 16 hours in the intensive care unit. The control group of smoking patients, in whom nicotine replacement therapy was not implemented, was formed by the selection method according to the match index with the first group. To form the group, the following criteria were used: sex, age, body mass index, length of smoking, EuroSCORE, left ventricular ejection fraction, concomitant diseases, off-pump coronary artery bypass grafting.<br /><strong>Results.</strong> In the immediate postoperative period the patients of both groups had episodes of delirium and agitation. Delirium developed less frequently in the group of patients receiving nicotine replacement therapy (34.7% vs 55.1%, p = 0.05). The average time of mechanical ventilation for patients with nicotine replacement therapy (3 h 35 min) was less than that for patients without nicotine replacement therapy (4 h 10 min). At the same time the groups did not differ from each other by the duration of their stay in intensive care unit, which was only one day.<br /><strong>Conclusion.</strong> Since smoking is a risk factor for the development of delirium, implementation of nicotine replacement therapy in smoking patients who underwent isolated myocardial revascularization can reduce not only the frequency of delirium in the early postoperative period, but also the duration of the ventilator support and the percentage of complications associated with it.</p><p>Received 10 August 2017. Revised 13 December 2017. Accepted 25 December 2017.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions</strong><br />Conception and study design: M.E. Evdokimov, A.A. Gornostaev, V.V. Bazylev<br />Data collection and analysis: M.E. Evdokimov, A.A. Gornostaev, A.A. Schegolkov, A.V. Bulygin, E.A. Malyarova <br />Statistical data analysis: A.A. Schegolkov, A.V. Bulygin<br />Drafting the article: I.S. Fomina, A.A. Schegolkov, A.V. Bulygin, E.A. Malyarova<br />Critical revision of the article: M.E. Evdokimov, A.A. Gornostaev, V.V. Bazylev <br />Final approval of the version to be published: V.V. Bazylev, M.E. Evdokimov, A.A. Gornostaev, I.S. Fomina, A.A. Schegolkov, A.V. Bulygin, E.A. Malyarova</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.